Similarly, a combination of PI3K and AKT inhibitors with chemotherapy agents has successfully attenuated chemotherapeutic resistance in a synergistic manner in GC cell lines [134, 136] and other cancer models [121], especially those characterized by PTEN loss [118]. Here, AKT1 is linked to gastric cancer.